Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …

Access to sufficient, safe, and nutritious food not only affects the health of people who
experience food insecurity, but also their ability to manage health conditions, such as …

Background Sulfonylureas are common second-line options for management of type 2
diabetes; however, they are associated with a higher risk of cardiovascular events compared …

OBJECTIVE The epidemic of type 2 diabetes (T2DM) threatens to become the major public
health problem of this century. However, a comprehensive comparison of the long-term …

Empagliflozin (Jardiance®), a potent, highly selective, sodium glucose cotransporter-2
(SGLT2) inhibitor, is an effective and generally well tolerated antihyperglycaemic agent …

A healthy adipose tissue (AT) is indispensable to human wellbeing. Among other roles, it
contributes to energy homeostasis and provides insulation for internal organs. Adipocytes …

OBJECTIVE To evaluate the efficacy and safety of dapagliflozin in patients with type 2
diabetes inadequately controlled with metformin and sulfonylurea. RESEARCH DESIGN …

Obesity, diabetes, and cardiovascular disease (CVD) present important unmet prevention
and treatment challenges. Dietary pulses are sustainable, affordable, and nutrientdense …

Based on data from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey,
this article provides national information about prescription medication use among …